AKT1 and acute lymphoblastic leukemia: These results demonstrate how the dual inhibition of Akt and mTOR could prove to be a promising therapeutic strategy, since hyperactivation of the PI3K/Akt/mTOR pathway represents a hallmark of ALL contributing to poor clinical outcomes [103].